简介:
- 作者: Andy Peng Xiang, Congyuan Liu, Hao Peng, Jiajie Yu, Hong Chen, Peng Luo, Yuanchen Ma, Wangsheng Ou, Suyuan Zhang, Cuifeng Yang, Hang Fan, Lerong Zhao, Yuchen Zhang, Xiaolu Guo, Qiong Ke, Tao Wang, Chunhua Deng, Weiqiang Li, Kai Xia
- 杂志: Research Square
- Doi: https://www.doi.org/10.21203/rs.3.rs-4788949/v1
- 出版日期: 2024 Aug 8
论文中使用的产品/服务
Quotation shows PackGene:Following sequencing-based verication, the constructed vector was custompackaged, puried, and titrated by Packgene Bioscience (Guangzhou, China). The
Research Field:Leydig Cells
AAV Serotype:AAVDJ
Targeted organ:testis
Animal or cell line strain:mice
摘要
Testicular aging commonly leads to testosterone deficiency and impaired spermatogenesis, yet the underlying mechanisms remain elusive. Here, a comprehensive analysis of senescence landscapes in mice testes during aging revealed that the Leydig cells (LCs) are particularly vulnerable to aging processes. Single-cell RNA sequencing identified the expression of Hmgcs2 (3-hydroxy-3-methylglutaryl-CoA synthetase 2), the gene encoding the rate-limiting enzyme of ketogenesis, decreased significantly in LCs from aged mice. Additionally, the concentrations of ketone bodies β-hydroxybutyric acid (BHB) and acetoacetic acid (AcAc) in the young testes were substantially higher than that in serum, but significantly diminished in aged testes. Silencing of Hmgcs2 in young LCs resulted in decreased ketone body production, which in turn drived LCs senescence and accelerated testicular aging. Mechanically, BHB acted as an endogenous inhibitor of histone deacetylase 1 to upregulate the expression of Foxo3a by promoting histone acetylation, thereby mitigating LCssenescence and promoting testosterone production. Consistently, enhanced ketogenesis by genetic manipulation or oral BHB supplementation alleviated LCs senescence and ameliorated testicular aging in aged mice. These findings highlight defective ketogenesis as a pivotal factor in testicular aging, suggesting novel therapeutic avenues for addressing age-related testicular dysfunction.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。